Published in Cancer on April 01, 1988
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med (1983) 8.82
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol (1983) 2.90
Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A (1993) 2.86
Minilaparotomy for the ambulatory management of ovarian cysts. Am J Obstet Gynecol (1995) 2.72
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer (1995) 2.64
BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science (1999) 2.54
Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol (1992) 2.43
Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol (1983) 2.33
Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet (1989) 2.20
Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res (1993) 1.89
Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res (1984) 1.83
Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene (2001) 1.82
CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol (1984) 1.61
Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol (1984) 1.60
Cancer of the uterine cervix. N Engl J Med (1996) 1.59
Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res (1995) 1.56
Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res (2000) 1.56
Risk factors for breast cancer. Am J Epidemiol (1983) 1.54
Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am J Obstet Gynecol (1974) 1.52
Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol (1993) 1.52
Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer (1999) 1.52
Expression of interleukin-1beta in human breast carcinoma. Cancer (1997) 1.52
Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer (1997) 1.50
Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol (1994) 1.48
Alcohol stimulates estrogen receptor signaling in human breast cancer cell lines. Cancer Res (2000) 1.46
Incidence and predictors of cervical dysplasia in patients with minimally abnormal Papanicolaou smears. Obstet Gynecol (1998) 1.45
Cellular senescence in a cloned strain of bovine fetal aortic endothelial cells. Science (1980) 1.41
Three-dimensional structure of Fab R19.9, a monoclonal murine antibody specific for the p-azobenzenearsonate group. Proc Natl Acad Sci U S A (1989) 1.35
An estimation of changes in the proportions and absolute numbers of hypoxic cells after irradiation of transplanted C3H mousemammary tumours. Br J Radiol (1969) 1.32
Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol (1985) 1.32
The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase. Oncogene (2000) 1.31
Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol (1984) 1.30
BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer (2006) 1.27
Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer (1998) 1.26
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene (2007) 1.24
Cigarette smoking and the risk of endometrial cancer. N Engl J Med (1985) 1.20
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril (1986) 1.19
CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol (1987) 1.19
BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene (1998) 1.18
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17
Invasive cervical carcinoma in young women. Gynecol Oncol (1979) 1.17
Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol (1988) 1.16
Letter: Comparison of tumour growth delay with cell survival. Br J Radiol (1974) 1.16
Response of avian embryonic brain to spatially segmented x-ray microbeams. Cell Mol Biol (Noisy-le-grand) (2001) 1.15
Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene (1997) 1.14
Pros and cons of gynecologic tumor markers. Cancer (1987) 1.14
The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol Cell Biol (2001) 1.13
Modulation of HGF-induced tubulogenesis and branching by multiple phosphorylation mechanisms. Dev Biol (1993) 1.13
The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res (1972) 1.12
Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer (1983) 1.12
Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett (2001) 1.12
Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer (1991) 1.12
Identification of cervical intraepithelial neoplasia (CIN) using UV-excited fluorescence and diffuse-reflectance tissue spectroscopy. Lasers Surg Med (2001) 1.12
Relationship of VH and VL genes encoding three idiotypic families of anti-p-azobenzenearsonate antibodies. Proc Natl Acad Sci U S A (1986) 1.11
Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol (1989) 1.11
Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med (1980) 1.11
Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol (1988) 1.10
Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene (1998) 1.10
Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab Invest (1997) 1.10
Signal transduction in c-met mediated motogenesis. EXS (1993) 1.10
Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med (1985) 1.10
Ovarian clear cell carcinoma. A clinicopathologic analysis of 44 cases. Int J Gynecol Pathol (1989) 1.10
Inhibitory effects of Indole-3-carbinol on invasion and migration in human breast cancer cells. Breast Cancer Res Treat (2000) 1.09
Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol (1986) 1.07
The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol (1986) 1.06
Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med (1982) 1.06
Proliferative characteristics of clonal endothelial cell strains. J Cell Physiol (1981) 1.05
Somatic activation of rasK gene in a human ovarian carcinoma. Science (1984) 1.05
Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. N Engl J Med (1980) 1.05
An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol (1988) 1.04
Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. Oncogene (1998) 1.04
Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res (1995) 1.02
Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci (1999) 1.02
Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol (1985) 1.01
Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience. J Clin Oncol (1984) 1.01
Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res (1992) 1.00
Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. Cancer (1980) 1.00
Effect of scatter factor and hepatocyte growth factor on motility and morphology of MDCK cells. In Vitro Cell Dev Biol (1992) 1.00
Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. J Nutr (2000) 1.00
Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma. Proc Natl Acad Sci U S A (1994) 1.00
Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. J Mol Med (Berl) (2000) 0.99
Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding. Oncogene (2001) 0.98
Relationship between obesity and uterine leiomyomata. Nutrition (1992) 0.98
Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity. J Immunol (1979) 0.98
Review of epidemiologic studies of endometrial cancer and exogenous estrogen. Obstet Gynecol (1979) 0.96
Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. J Natl Cancer Inst (1980) 0.96
Aortic lymph node metastases in early ovarian cancer. Am J Obstet Gynecol (1974) 0.96
A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells. J Immunol (1989) 0.96
Co-expression of human cancer-associated epitopes on mucin molecules. Int J Cancer (1987) 0.95